Dr. Neelima Vidula is a breast medical oncologist at Massachusetts General Hospital (MGH) and an Assistant Professor of Medicine at Harvard Medical School in Boston, MA. Dr. Vidula completed medical school and residency in internal medicine at Northwestern University in Chicago, IL, and a fellowship in hematology and medical oncology at the University of California San Francisco in San Francisco, CA.
Dr. Vidula is the principal investigator of many early phase clinical trials studying novel agents for patients with breast cancer. Among these trials, she is the lead national principal investigator of an investigator initiated clinical trial exploring immunotherapy and chemotherapy for breast cancer associated-chest wall disease, which she is running through the Translational Breast Cancer Research Consortium. She is the Founder of the Breast Cancer with Chest Wall Disease Comprehensive Program at MGH which includes a multidisciplinary clinic for patients with chest wall disease, as well as an accompanying clinical and translational research program. Dr. Vidula is also the lead national principal investigator of another investigator initiated clinical trial evaluating a PARP inhibitor in somatic BRCA mutant metastatic breast cancer, which is funded by a Conquer Cancer Foundation of ASCO – Breast Cancer Research Foundation – Career Development Award and Pfizer ASPIRE award. Dr. Vidula also performs clinical research evaluating the impact of biomarkers on therapy response and patient outcomes, and conducts research in precision medicine using cell-free DNA and tumor genotyping. She has presented her research at several national and international meetings, and published articles in high-impact journals.